Insulin dose reduction during exercise yields similar glucose effects with ultra-rapid and rapid aspart
A randomized controlled trial in 43 adults with type 1 diabetes compared ultra-rapid-acting insulin aspart (URA-IAsp) to rapid-acting insulin aspart (IAsp) during laboratory-controlled moderate-intensity exercise. Participants received either insulin type at 50% or 75% reduced doses before exercise, with blood glucose and insulin concentrations monitored for 4 hours after the second insulin injection.
During exercise, blood glucose declined similarly across conditions: -4.0 ± 2.8 mmol/L with 50% dose URA-IAsp, -5.1 ± 3.0 mmol/L with 50% dose IAsp, -2.8 ± 3.3 mmol/L with 75% dose URA-IAsp, and -3.4 ± 3.3 mmol/L with 75% dose IAsp. The comparison between 50% dose URA-IAsp and all other conditions showed no significant difference (all p > 0.05). However, the 50% IAsp dose produced significantly greater glucose decline than both 75% reduced dose conditions (p < 0.05). Insulin concentrations differed only by dose amount, not insulin type, from 30 minutes after the first injection.
Safety and tolerability data were not reported. The study was conducted under specific laboratory conditions with a standardized exercise protocol, limiting generalizability to different exercise types, intensities, or durations. Clinical outcomes like hypoglycemia events and patient-reported outcomes were not assessed. While the RCT design supports causal inference for the tested interventions under study conditions, these findings represent preliminary evidence from a single controlled trial. The results suggest that insulin dose reduction magnitude may be more important than insulin type for managing glycemia during moderate exercise in type 1 diabetes, but real-world applicability requires further investigation.